cefotaxime and Impetigo

Cefotiam was evaluated by a comparative open-label randomized trial with cephalothin in the therapy of skin and soft tissue infections in 39 patients. The most common organism isolated was Staphylococcus aureus (78%). We established evidence of primary infection with gram-negative bacilli in four patients, three of whom were diabetic. Eight patients had mixed infections or superinfections. No patient was evaluated as a treatment failure; for 10 of 39 patients we were unable to recover an etiological agent but demonstrated a clinical cure. Cefotiam was found to be as effective as cephalothin in the therapy of skin and soft tissue infections.

Topics: Adult; Aged; Bacterial Infections; Cefotaxime; Cefotiam; Cellulitis; Cephalothin; Drug Evaluation; Humans; Impetigo; Male; Microbial Sensitivity Tests; Middle Aged; Random Allocation

Topics: Administration, Intravenous; Anti-Bacterial Agents; Biopsy; Blister; Cefotaxime; Dermis; Humans; Impetigo; Infant, Newborn; Male; Staphylococcal Scalded Skin Syndrome; Staphylococcus aureus

Since the mid-1980s, an increase in incidence of invasive disease caused by group A streptococci has been noted among adults and children. The characteristic clinical and laboratory features of the streptococcal toxic shock syndrome include deep-seated infection associated with shock, skin manifestation, and multiorgan failure. However, bullous impetigo is invariably considered to be a staphylococcal disease. Staphylococcus aureus produces an epidermolytic toxin, assumed to be the cause of bullous formation in the skin. Here, we present a case of bullous impetigo in an infant with streptococcal toxic shock syndrome. This is a rare presentation of bullous impetigo caused by group A streptococcus.

Topics: Anti-Bacterial Agents; Cardiotonic Agents; Cefotaxime; Clindamycin; Colloids; Combined Modality Therapy; Disseminated Intravascular Coagulation; Female; Humans; Impetigo; Infant; Plasma; Respiration, Artificial; Shock, Septic; Skin Diseases, Vesiculobullous; Streptococcal Infections; Streptococcus pyogenes; Vancomycin; Vitamin K

We present a case of nonbullous impetigo neonatorum associated with late onset group B streptococcal meningitis in a 12-day-old infant. Both skin lesions and meningitis resolved with antibiotic therapy. This is the first reported case of meningitis during the course of this skin disease.

Topics: Anti-Bacterial Agents; Cefotaxime; Humans; Impetigo; Infant, Newborn; Male; Meningitis, Bacterial; Streptococcal Infections